MOPVP
MOPVP (4'-methoxy-alpha-pyrrolidinopentiophenone) is a pyrrolidine synthetic cathinone in the alpha-PVP family, bearing a methoxy substituent on the aromatic ring. Sold as a research chemical, it acts as a potent dopamine reuptake inhibitor. There is essentially no human data; all information is anecdotal.
01 Overview
MOPVP is a methoxy-substituted analogue of alpha-PVP, marketed as a legal-grey stimulant. Users report potent, focused stimulation with the strong compulsive character typical of the PVP series, though the methoxy group is reported to soften the euphoria somewhat.
As a pyrrolidine cathinone it carries a heightened risk of compulsive redosing and binge use, plus cardiovascular strain, comedown and unknown neurotoxicity. No controlled human studies exist; figures are approximate.
02 Mechanism
Potent, selective noradrenaline-dopamine reuptake inhibitor at the dopamine and noradrenaline transporters, characteristic of alpha-PVP analogues.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common | 7–20 mg | Insufflated | Very compulsive. |
| Common | 10–30 mg | Oral | Anecdotal; potent, start low. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Intense stimulationStrong energy and focus. | Anecdotal | ||
| EuphoriaDopaminergic mood elevation, milder than alpha-PVP per reports. | Anecdotal | ||
| Appetite suppressionMarked hunger reduction. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Compulsive redosingPowerful redosing compulsion typical of the PVP series. | Severe | Near universal | Anecdotal | |
| Cardiovascular strainTachycardia and hypertension. | Severe | Common | Unconfirmed | |
| Stimulant psychosisParanoia and hallucinations after binges and sleep loss. | Severe | Uncommon | Unconfirmed |